| Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19) (NCT07712588) | Dizal Pharmaceuticals | 2026-09-01 |
| Assessing Treatment of T-Cell Lymphoma With GW5282 in Combination With Golidocitinib (BEI-DOU3) (NCT07496229) | Dizal Pharmaceuticals | 2026-04-15 |
| A Mass Balance Study of DZD8586 in Healthy Male Participants (TAI-SHAN15) (NCT07454863) | Dizal Pharmaceuticals | 2026-03-16 |
| A Phase 1/2 Study of GW5282 in Participants With Advanced Solid Tumors (NCT07328217) | Dizal Pharmaceuticals | 2026-01-29 |
| A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11) (NCT07294365) | Dizal Pharmaceuticals | 2026-01-15 |
| A Study of DZD8586 Combination in CLL/SLL (TAI-SHAN10) (NCT07154264) | Dizal Pharmaceuticals | 2025-09-22 |
| A Study of DZD8586 Versus Investigator's Choice in r/r CLL/SLL (TAI-SHAN6) (NCT07139873) | Dizal Pharmaceuticals | 2025-09-08 |
| DZD8586 Combination Therapy in Patients With Diffuse Large B-cell Lymphoma (TAI-SHAN12) (NCT07059650) | Dizal Pharmaceuticals | 2025-08-19 |
| DZD6008 Combination Therapy in Patients With Locally Advanced or Metastatic NSCLC With EGFR Mutation (TIAN-SHAN7) (NCT07070440) | Dizal Pharmaceuticals | 2025-07-16 |
| A Multinational Study Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN1) (NCT06905197) | Dizal Pharmaceuticals | 2025-05-13 |
| Assessing an Oral EGFR Inhibitor, DZD6008 in Patients Who Have Advanced NSCLC With EGFR Mutations (TIAN-SHAN2) (NCT06813365) | Dizal Pharmaceuticals | 2024-06-12 |
| A Phase 3 Multinational Study of Golidocitinib Versus Investigator's Choice in r/r PTCL (JACKPOT19) (NCT07234162) | Dizal Pharmaceuticals | 2024-05-13 |
| DZD8586 in Patients With Relapsed or Refractory CLL/SLL (TAI-SHAN8) (NCT06539182) | Dizal Pharmaceuticals | 2024-04-29 |
| DZD8586 in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (TAI-SHAN9) (NCT06539195) | Dizal Pharmaceuticals | 2024-03-13 |
| DZD9008 PK Study in Hepatic Impairment Subjects (NCT06084104) | Dizal Pharmaceuticals | 2023-10-17 |
| Assessing the Effect of DZD9008 on the Pharmacokinetics of the Cocktail Probes Representative for CYP3A4, P-gp, BCRP and OATP1B1 in Patients with EGFR or HER2 Mutant Advanced Non-small Cell Lung Cancer (WU-KONG19) (NCT05926180) | Dizal Pharmaceuticals | 2023-07-31 |
| A Phase II Clinical Trial of DZD9008 in Combination With AZD4205 in Standard Treatment Failed NSCLC Patients With EGFR Mutations (WU-KONG21) (NCT06295432) | Dizal Pharmaceuticals | 2023-06-01 |
| DZD9008 In Combination With Bevacizumab in Locally Advanced or Metastatic NSCLC Patients With EGFR Mutation (WU-KONG29) (NCT06276283) | Dizal Pharmaceuticals | 2023-02-15 |
| A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28) (NCT05668988) | Dizal Pharmaceuticals | 2022-12-13 |
| Drug-drug Interactions Between AZD4205 and Itraconazole/Carbamazepine (NCT05486949) | Dizal Pharmaceuticals | 2022-07-27 |
| A Study of DZD8586 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (TAI-SHAN1) (NCT05844956) | Dizal Pharmaceuticals | 2022-06-01 |
| AZD4205 in Relapsed or Refractory Peripheral T Cell Lymphoma (JACKPOT27) (NCT06511895) | Dizal Pharmaceuticals | 2022-05-31 |
| AZD4205 in Peripheral T Cell Lymphoma Following First-Line Therapy (JACKPOT26) (NCT06511869) | Dizal Pharmaceuticals | 2022-03-17 |
| Drug-drug Interactions Between DZD9008 and Itraconazole/Carbamazepine (NCT05418582) | Dizal Pharmaceuticals | 2022-01-25 |
| Pharmacokinetic and Mass Balance Study of Oral-Administrated [14C]-DZD9008 in Healthy Male Subjects (NCT05159895) | Dizal Pharmaceuticals | 2021-09-24 |
| Assessing an Oral Bruton Tyrosine Kinase Inhibitor, DZD9008 in Patients Who Have Non-Hodgkin B-cell Lymphoma (WU-KONG3) (NCT04148742) | Dizal Pharmaceuticals | 2021-08-01 |
| Sunvozertinib (DZD9008) in Pretreated Lung Cancer Patients with EGFR Exon20 Insertion Mutation (WU-KONG6) (NCT05712902) | Dizal Pharmaceuticals | 2021-07-19 |
| A Study of DZD2269 in Healthy Adult Participants (NCT04932005) | Dizal Pharmaceuticals | 2021-06-29 |
| Assess the Safety, Tolerability, PK and Anti-tumor Efficacy of DZD2269 in Patients With MCRPC (NCT04634344) | Dizal Pharmaceuticals | 2021-04-12 |
| DZD1516 in Combination With Trastuzumab and Capecitabine, or in Combination With T-DM1, in Patients With Metastatic HER2 Positive Breast Cancer (NCT04509596) | Dizal Pharmaceuticals | 2020-09-21 |
| Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-AZD4205 in Healthy Adult Male Volunteers (NCT04225208) | Dizal Pharmaceuticals | 2020-01-06 |
| Assessing an Oral EGFR Inhibitor, Sunvozertinib in Patients Who Have Advanced Non-small Cell Lung Cancer With EGFR or HER2 Mutation (WU-KONG1) (NCT03974022) | Dizal Pharmaceuticals | 2019-07-09 |
| A Study of AZD4205 in Healthy Adult Subjects (NCT03728023) | Dizal Pharmaceuticals | 2018-11-12 |
| Assessing an Oral Janus Kinase Inhibitor, AZD4205, in Combination With Osimertinib in Patients Who Have Advanced Non-small Cell Lung Cancer (NCT03450330) | Dizal Pharmaceuticals | 2018-04-16 |